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Organ damage (SLICC)Abstract Aim of the work: The aim of our study was to assess the serum levels of transforming
growth factor-b1 (TGF-b1) in Egyptian systemic lupus erythematosus (SLE) patients in order to
determine whether these levels are associated with disease activity and organ damage.
Patients and methods: Serum level of TGF-b1 was assessed in 70 Egyptian SLE patients and 60
healthy subjects using ELISA. The levels were related to clinical features, disease activity as assessed
by the SLE disease activity index (SLEDAI) and damage assessed by the Systemic Lupus
International Collaborating Clinics (SLICC) index.
Results: Serum levels of TGF-b1 were signiﬁcantly reduced in patients with SLE compared to
levels in healthy controls (875.8 ± 292.2 pg/ml vs 1140 ± 301 pg/ml, respectively) (p< 0.001).
TGF-b1 levels signiﬁcantly correlated with hemoglobin content, platelet counts, and inversely with
the erythrocyte sedimentation rate (ESR), serum creatinine and urea. Signiﬁcantly lower TGF-b1
levels were found in patients with high disease activity (SLEDAI > 10) while the level tended to
be lower in those with organ damage. TGF-b1 was signiﬁcantly lower in patients with serum
creatinine >1.2 mg/dl than in those with <1.2 mg/dl (p= 0.003), and also in patients with
glomerular ﬁltration rate (GFR) <50 ml/min than in those with >50 ml/min (p= 0.038).
Conclusion: This study demonstrated signiﬁcantly reduced serum levels of TGF-b1 in patients
with SLE compared with healthy subjects. Lower serum TGF-b1 levels were associated with high
disease activity and organ damage in SLE patients. A prominent role in renal damage was observed.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Systemic lupus erythematosus (SLE) is a chronic systemic
autoimmune disease with variable clinical presentation. SLE
S50 S.A. Metawie et al.can affect all organs and the involvement of major organs can
be life threatening. The exact pathological mechanisms of SLE
remain elusive, and the etiology of SLE is known to be multi-
factorial [1]. Measuring organ damage in SLE is important
with special concern to juvenile-onset patients to allow for
designing new treatments that improve control of disease
activity and minimize the development of irreversible damage.
The kidney appeared to be commonly involved, especially in
males, indicating the importance of regular screening for early
and appropriate management [2].
Several key player factors play a signiﬁcant role in the
pathogenesis of SLE such as cytokine overproduction [3,4],
oxidative stress [5] and apoptosis [6]. Comorbidities as meta-
bolic syndrome [7], dyslipidemia and atherosclerosis [8] could
lead to functional disability, impaired quality of life and
signiﬁcantly affect the disease activity and damage. Many
proinﬂammatory cytokines were found to play a prominent
role in the pathogenesis of SLE; while anti-inﬂammatory
cytokines, such as interleukin-4 (IL-4), IL-10 and TGF-b1
were important to preserve a balance in the cytokine milieu
[9]. In a study on Egyptian SLE patients, serum levels of
IL-4 were signiﬁcantly lower while both IL-17 and inter-
feron-gamma (IFN-c) were signiﬁcantly higher in SLE patients
and the latter 2 cytokines were considered as biomarkers of
renal activity [10]. Similarly, studies on other proinﬂammatory
and central factors as IL-18 [11], B-lymphocyte stimulator
(BLyS) [12], resistin [13], matrix metalloproteinase [14] and
growth arrest speciﬁc protein-6 (gas6) [15], showed that they
may have a pathogenic role in the development of SLE and
play a crucial role in the development, triggering of activity
and severity in lupus nephritis.
The transforming growth factor b (TGF-b) family of
cytokines encompasses three closely related members:
TGF-b1, TGF-b2, and TGF-b3. Lymphocytes and mono-
cytes produce the b1 isoform of this cytokine which exerts
a major immune regulatory function [16]. TGF-b1 is the most
potent naturally occurring immunosuppressant; it plays a
fundamental role in controlling proliferation and the fate of
cells through apoptosis. TGF-b1 is an important negative
regulator of B cell differentiation and proliferation, inhibiting
the production of most immunoglobulin iso-types [17]. It also
serves as a co-stimulatory factor in the development of T cells
with down-regulatory activities [18]. TGF-b1 might play a
dual role during the development and progression of
immune-mediated inﬂammatory diseases. TGF-b1 production
by lymphocytes is reduced in SLE, this might predispose to
autoreactive T cell activation and autoantibody production.
In autoimmune diseases, inﬁltration of target organs, such
as kidneys, with T cells or deposition of autoantibody-
containing immune complexes causes early inﬂammatory
lesions that trigger the local production of anti-inﬂammatory
cytokines such as TGF-b1 by macrophages and renal mesan-
gial cells to counter inﬂammation [19]. The enhanced TGF-b1
production in tissues induces local ﬁbrogenesis and ultimately
causes fulminant organ damage [20]. So any treatment for
SLE that involved manipulation of TGF-b1 would need to
be approached with caution considering effects on the cyto-
kine network as a whole [21].
The aim of our study was to assess the serum levels of TGF-
b1 in 70 Egyptian patients with SLE and 60 healthy subjects.
Serum levels of TGF-b1were related to disease-related variablesin order to determine whether serum levels of TGF-b1 might
associate to disease activity and organ damage in SLE.2. Patients and methods
This is a case-control study, in which 70 SLE patients diag-
nosed according to the 2012 Systemic Lupus International
Collaborating Clinics (SLICC) classiﬁcation criteria [22], were
studied. All patients were recruited from the Rheumatology
and Rehabilitation Department, Kasr Al Ainy hospital Cairo
University. Approval for the study was obtained from the
Rheumatology and Rehabilitation and also the Clinical
Pathology Departments (according to the WMA Declaration
of Helsinki). All patients received a thorough explanation of
the study design and aims, and were provided with written
informed consent. Sixty healthy subjects served as controls
and were matched to the cases as closely as possible for age
(with mean of 31.37 ± 6.5 years old), sex (52 females and 8
males), and ethnic group.
Disease activity was assessed with the Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI) [23].
Disease damage was recorded according to the Systemic
Lupus International Collaborating Clinics/American College
of Rheumatology (SLICC/ACR) Damage Index [24]. The
grades of disease activity were deﬁned as SLEDAI 0 = quies-
cent disease, SLEDAI 1–10 = moderate activity, and SLEDAI
>10 = high disease activity. The cut-off for organ damage
was SLICC 0 = no organ damage, SLICC 1–3 = moderate
organ damage, and SLICC >3 = severe organ damage.
SLE patients were divided into different groups according
to the following criteria denoting renal damage; 24-h urinary
protein over 3.5 gm/dl or not; glomerular ﬁltration rate
(GFR) less than 50 ml/min or not; serum creatinine over
1.2 mg/dl or not.
In attempt to elucidate the importance of TGF-b1 for the
development of SLE, we measured serum levels of TGF-b1
in 70 patients with SLE and in 60 healthy controls.
2.1. Measurement of serum TGF-b1 concentration
Peripheral blood samples were obtained from all subjects.
Serum samples were collected and stored frozen at 20 C until
assayed. The concentrations of TGF-b1 protein in the serum
samples were measured by quantitative sandwich enzyme
linked immunosorbent assay (ELISA) technique, using com-
mercially available kits (Human TGF-beta1 Platinum ELISA
Bioscience Cat No BMS249/4). The results were calculated
by reference to the standard curve and expressed as pg/ml.
Statistical analysis: All data were tabulated, statistically
analyzed. The data were coded and entered using the software
SPSS (Statistical package for social science) version 15. The
data were summarized using descriptive statistics: mean, stan-
dard deviation, minimal and maximum values for quantitative
variables and number and percentage for qualitative values.
Statistical differences between groups were tested using Chi
Square test for qualitative variables, independent sample t test
for quantitative normally distributed variables while non para-
metric Mann Whitney test was used for quantitative variables
which are not normally distributed. The correlation between
serum TGFB1 level and disease-related variables was assessed
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considered statistically signiﬁcant.
3. Results
The study included 70 SLE patients with a mean age of
28.04 ± 9.3 years. They were 65 females and 5 males.
Demographic data, medications received and disease-related
variables of SLE patients are shown in Table 1.
In this case-control study, the serum level of TGF b1 in SLE
patients ranged from 170 to 1900 pg/ml with a mean of
875.8 ± 292.2 pg/ml, while its level in the control group ranged
from 670 to 1900 pg/ml with a mean of 1140 ± 301 pg/ml.
Comparison between levels of serum TGF b1 in SLE patientsTable 1 Demographic data, medications received and disease
related variables in systemic lupus erythematosus (SLE)
patients.
Variable SLE patients (n= 70)
Age (years) 28.04 ± 9.3
Disease duration (months) 64.5 ± 58.5
Female sex 65 (92.9)
ESR (mm/h) 58.5 ± 35.7
Hemoglobin (gm/dl) 10.4 ± 2.1
WBCs (103/lL) 7.8 ± 3.2
Platelets (103/lL) 283 ± 109.1
Serum creatinine (mg/dl) 1.2 ± 1.38
Blood urea (mg/dl) 60.4 ± 53.2
24 h urinary proteins (gm/dl) 2.3 ± 0.1
GFR< 50 ml/min 10 (14.3)
ANA positivity 70 (100)
Anti-ds DNA positivity 64 (91.4)
ACL positivity 6 (8.6)
LAC positivity 4 (5.7)
Malar rash 51 (72.9)
Arthritis 57 (81.4)
Vasculitis 12 (17.1)
Lupus nephritis 55 (78.6)
Lupus cerebritis 22 (32.5)
Medications received
Corticosteroids 68 (97.1)
Hydroxychloroquine 64 (91.4)
Azathioprine 21 (30)
Cyclophosphamide 32 (45.7)
Mycophenolate mofetil 5 (7.1)
SLEDAI score 10.4 ± 7.2
Score = zero (quiescent) 3 (4.3)
Score = 1–10 (moderate) 36 (51.4)
Score > 10 (high) 31 (44.3)
SLICC/ACR DI score 0.7 ± 0.9
Score = zero 40 (57.1)
Score = 1–3 (moderate) 30 (42.9)
Score > 3 (severe) 0 (0)
ESR: erythrocyte sedimentation rate, WBC: white blood cells,
GFR: glomerular ﬁltration rate, ANA: anti-nuclear antibodies,
ds-DNA: double stranded deoxyribonucleic acid, ACL: antic-
ardiolipin, LAC: lupus anticoagulant, SLEDAI: Systemic Lupus
Erythematosus Disease Activity Index, SLICC/ACR DI: Systemic
Lupus International Collaborating Clinics/American College of
Rheumatology damage index. Results are presented as Mean ± SD
or number (percentage).and the control group showed a statistically signiﬁcant differ-
ence, being lower in SLE patients (p< 0.001).
Correlating serum TGF-b1 to disease-related variables in
SLE patients, showed a statistically signiﬁcant correlation with
hemoglobin (Hb) and platelet counts and negatively with
serum creatinine, urea, erythrocyte sedimentation rate (ESR)
and total SLEDAI score. No signiﬁcant correlation was
detected between serum TGF-b1 and SLICC/ACR damage
index (Table 2).
On comparison of the serum TGF-b1 levels according to
renal damage, a statistically signiﬁcant difference was found
between patients with GFR <50 ml/min and those with
>50 ml/min (p= 0.038) (Fig. 1). No statistically signiﬁcant
difference was found between serum TGF-b1 in patients with
24-h urine protein over 3.5 gm/dl and patients with
<3.5 gm/dl (p= 0.65). A statistically signiﬁcant lower TGF-
b1 was found in patients with serum creatinine >1.2 mg/dl
compared to those <1.2 mg/dl (p= 0.003) (Fig. 2 and
Table 3).
Comparison between SLE patients with moderate SLEDAI
versus those with higher SLEDAI as regards serum TGF-b1
levels (954.4 ± 327.6 and 779.8 ± 230.5 pg/ml, respectively)
showed a signiﬁcant difference (p= 0.025). Comparison
between SLE patients with no organ damage and those with
moderate organ damage (SLICC/ACR score 1–3) as regards
serum TGF-b1 levels (929.1 ± 310.4 and 804.6 ± 253.7,
respectively) showed no signiﬁcant difference (p= 0.088).
We found lower serum levels of TGF-b1 in patients with
malar rash, vasculitis, arthritis nephritis and cerebritis than
in those without these clinical features but the difference was
not statistically signiﬁcant (data not shown).4. Discussion
TGF-b1 knockout mice developed a SLE-like disorder with
various autoantibodies, suggesting the possible involvement
of TGF-b1 in the pathogenesis of SLE [25]. Preliminary
human studies suggest that TGF-b1 expression in SLE may
be dysregulated [26].
The present study showed a statistically signiﬁcant differ-
ence between patients with SLE and the healthy subjects
regarding serum TGF-b1 levels, being lower in patients. This
is in concordance to other studies [16,27] that found that serum
levels of TGF-b1 were signiﬁcantly reduced in patients with
SLE compared with levels in healthy controls. They attributed
their ﬁndings to impaired production of TGF-b1 by lympho-
cytes isolated from SLE patients. Another study done by
Xing et al. [28] revealed that the concentration of serum
TGF-b1 was markedly decreased in SLE patients in parallel
with reduced peripheral T regulatory cells. Although Kohut
et al. [29] in their study showed that TGF-b1 mRNA produc-
tion is defective in T and B cells isolated from SLE patients’
peripheral blood, they found slightly increased serum TGF-b1
levels in SLE patients than in controls. They attributed these
paradoxical ﬁndings by the potential production of TGF-b1
by monocytes and other non lymphoid cells. In another study
on Egyptian rheumatoid arthritis patients, there was a twofold
increase in the TGF-b level proving a disturbance in the cyto-
kine milieu in favor of inﬂammation and drawing attention to
its importance in the pathogenesis of this other autoimmune
disease [9].
Table 2 Correlation between serum TGF-b1 and disease-related variables in systemic lupus erythematosus (SLE) patients.
Variable Serum TGF-b1 (pg/ml) in SLE patients (n= 70)
R p
SLEDAI score 0.37 0.002*
SLICC/ACR DI score 0.24 0.05
ESR (mm/h) 0.3 0.013*
Hemoglobin (gm/dl) 0.3 0.012*
WBC (103/lL) 0.03 0.81
Platelets (103/lL) 0.33 0.005*
Creatinine (mg/dl) 0.33 0.005*
Urea (mg/dl) 0.29 0.014*
24 h urinary proteins (gm/dl) 0.12 0.35
Cholesterol 0.16 0.52
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index, SLICC/ACR DI: Systemic Lupus International Collaborating Clinics/
American College of Rheumatology Damage Index, ESR: erythrocyte sedimentation rate, WBCs: white blood cells.
* p< 0.05 is considered statistically signiﬁcant.
Figure 1 Comparison between serum TGFb1 in SLE patients
with Glomerular ﬁltration rate (GFR) <50 ml/min and P50 ml/
min.
Figure 2 Comparison between serum level of TGFb1 in SLE
patients with creatinine 61.2 mg/dl and patients with creatinine
>1.2 mg/dl.
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TGF-b1 and both Hb and platelet counts. While there was a
signiﬁcant negative correlation between it and serum crea-
tinine, urea, ESR and total SLEDAI score. This is in concor-
dance to the ﬁndings of other studies that revealed a
signiﬁcantly negative correlation between serum TGF-b1 and
SLEDAI score [30,31]. Also Jin and his colleagues [16] showed
a signiﬁcant correlation between serum TGF-b1 and white
blood cells counts and platelet counts, while there was a signiﬁ-
cant negative correlation between it and ESR. They suggested
that the strong correlation between TGF-b1 levels and blood
platelet numbers might indicate that the platelets might be
another reservoir of importance for TGF-b1 levels in patients
with SLE. They also suggested that the inverse correlation
between TGF-b1 and ESR might indicate that low level of
TGF-b1 might be a valuable tool for determining disease
activity.In the present study malar rash was present in 72.9%,
arthritis in 81.4%, vasculitis in 17.1%, lupus nephritis in
78.6% and cerebritis in 32.5%. The mean SLEDAI was
10.39 ± 7.2 and SLICC was 0.67 ± 0.93. These ﬁndings are
comparable and in harmony with those found in another
Egyptian study [32] on a cohort of SLE patients where the
mucocutaneous manifestations were found in 72.5%, arthritis
in 67.5%, nephritis in 79.5, neuropsychiatric in 38.5% and
SLEDAI was 9.95 ± 8.2 however; vasculitis was present in
3.5% and SLICC was much higher (2.7 ± 2.2).
In our study, SLE patients were divided into different sub-
groups regarding disease activity (SLEDAI) and organ dam-
age (SLICC). The levels of serum TGF-b1 were signiﬁcantly
lower in patients with high disease activity than in patients
with moderate activity. Lower levels of serum TGF-b1 were
found in patients with organ damage than in patients without.
Table 3 Comparison between the three groups denoting renal damage as regards serum TGF-b1 levels in systemic lupus
erythematosus (SLE) patients.
Mean ± SD Serum TGF-b1 (pg/ml) in SLE patients (n= 70) p
24 h urinary protein (gm/dl) 0.65
P3.5 912.3 ± 322.4
<3.5 875.8 ± 282.8
Creatinine (mg/dl) 0.003*
>1.2 692.9 ± 238
61.2 934.4 ± 285.3
GFR (ml/min) 0.038*
P50 909.5 ± 281.1
<50 673 ± 287.9
GFR: glomerular ﬁltration rate, TGF: Transforming growth factor.
* p< 0.05 is considered statistically signiﬁcant.
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found lower serum TGF-b1 levels in patients with high disease
activity and severe organ damage [16].
We found signiﬁcantly lower levels of serum TGF-b1 in
patients with renal damage as presented by those with a
GFR <50 ml/min and those with a serum creatinine
>1.2 mg/dl. This was in agreement with the results of Jin
et al. [16] who found a signiﬁcantly lower level of serum
TGF-b1 in patients with renal damage (24-h urine protein
>3.5 g/dl; GFR <50 ml/min, creatinine >90 mmol/l). In
SLE patients, the expression and signaling of the TGF-b1 sys-
tem might be activated in a local inﬂamed organ, for example
in the kidneys, although systemic levels are decreased. This was
demonstrated by Saxena et al. [19] who measured TGF-b1
concentrations in kidneys and urine of lupus mice and found
that they correlated with the extent of chronic kidney disease.
Currently, the treatment for SLE has evolved from conven-
tional drugs such as corticosteroids and immunosuppressants
to biologic agents. Various therapeutic agents targeting
different cytokines have been developed to treat SLE. The efﬁ-
cacy of these agents is believed to depend on speciﬁc disease
condition, different organs involved, and timing of medication,
indicating a spatial and temporal variety of cytokine expres-
sion in SLE, which provide challenge for cytokine-targeted
therapy for SLE and necessitate further investigation [33].
It is noteworthy to mention that performing this study on a
larger number of patients longitudinally and taking into
consideration the gender differences, medications received
and antiphospholipid status are suggested in the future and
considered as limitations of this work.
We concluded that in SLE lowered serum TGF-b1 level
might be a feature of systemic immune dysfunction, which
might be associated to disease susceptibility, activity, organ
damage and might have a role in the pathogenesis of renal
involvement in those patients. However, further studies are
recommended to evaluate the use of serum TGF-b1 as a
non-invasive marker for assessment of activity and organ
damage and to determine its plausible role as a therapeutic
target of interest in SLE.
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